SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-017587
Filing Date
2023-05-11
Accepted
2023-05-11 16:27:34
Documents
52
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rgls-20230331.htm   iXBRL 10-Q 1281578
2 EX-31.1 ex-311x20230331.htm EX-31.1 9806
3 EX-31.2 ex-312x20230331.htm EX-31.2 9783
4 EX-32.1 ex-321x20230331.htm EX-32.1 9674
  Complete submission text file 0001628280-23-017587.txt   5118420

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgls-20230331.xsd EX-101.SCH 29994
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgls-20230331_cal.xml EX-101.CAL 52764
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgls-20230331_def.xml EX-101.DEF 194969
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgls-20230331_lab.xml EX-101.LAB 453659
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgls-20230331_pre.xml EX-101.PRE 290167
46 EXTRACTED XBRL INSTANCE DOCUMENT rgls-20230331_htm.xml XML 652250
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35670 | Film No.: 23911479
SIC: 2834 Pharmaceutical Preparations